Literature DB >> 9108082

"Autoimmune rejection" of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue.

R L Tarleton1, L Zhang, M O Downs.   

Abstract

Infection with the protozoan parasite Trypanosoma cruzi often results in chronic heart- and gut-associated disease known as Chagas disease. In this study we show that contrary to previous reports, neonatal hearts transplanted into mice chronically infected with T. cruzi do not exhibit signs of autoimmune-type rejection or any significant inflammatory response. In addition to an absence of inflammation, these syngeneic heart transplants survive for more than 1 year and are absolutely free of parasites as determined by in situ PCR analysis. However, if well-established transplanted hearts in chronically infected mice are directly injected with live parasites, a rapid and dramatic inflammatory response ensues that results in cessation of heart function. Likewise, transplanted hearts established in mice prior to systemic infection with T. cruzi or hearts transplanted into mice during the acute stage of T. cruzi infection become parasitized and develop inflammatory foci. In these cases where the transplanted hearts become parasitized, the ensuing inflammatory response is nearly identical to that observed in the native hearts of T. cruzi-infected mice in terms of cell types present and adhesion molecules and cytokines expressed. Importantly, this response is strikingly different from that observed in the allogeneic heart rejection. These results clearly document that parasitization of heart tissue is both necessary and sufficient for the induction of tissue damage in Chagas disease and strongly argue against a principal autoimmune etiology for this disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108082      PMCID: PMC20545          DOI: 10.1073/pnas.94.8.3932

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Quantitative comparison between xenodiagnosis and haemoculture in the detection of Trypanosoma (Schizotrypanum) cruzi in experimental and natural chronic infections.

Authors:  E Minter-Goedbloed; D M Minter; T F Marshall
Journal:  Trans R Soc Trop Med Hyg       Date:  1978       Impact factor: 2.184

2.  Amplification of a Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy.

Authors:  E M Jones; D G Colley; S Tostes; E R Lopes; C L Vnencak-Jones; T L McCurley
Journal:  Am J Trop Med Hyg       Date:  1993-03       Impact factor: 2.345

3.  Depletion of T-cell subpopulations results in exacerbation of myocarditis and parasitism in experimental Chagas' disease.

Authors:  R L Tarleton; J Sun; L Zhang; M Postan
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

4.  Studies of Trypanosoma cruzi clones in inbred mice. III. Histopathological and electrocardiographical responses to chronic infection.

Authors:  M Postan; J J Bailey; J A Dvorak; J P McDaniel; E W Pottala
Journal:  Am J Trop Med Hyg       Date:  1987-11       Impact factor: 2.345

5.  Molecular mimicry by Trypanosoma cruzi: the F1-160 epitope that mimics mammalian nerve can be mapped to a 12-amino acid peptide.

Authors:  W C Van Voorhis; L Schlekewy; H L Trong
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

6.  Trypanosoma cruzi infection in MHC-deficient mice: further evidence for the role of both class I- and class II-restricted T cells in immune resistance and disease.

Authors:  R L Tarleton; M J Grusby; M Postan; L H Glimcher
Journal:  Int Immunol       Date:  1996-01       Impact factor: 4.823

7.  Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up.

Authors:  R Viotti; C Vigliano; H Armenti; E Segura
Journal:  Am Heart J       Date:  1994-01       Impact factor: 4.749

8.  Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains.

Authors:  S G Andrade; A Rassi; J B Magalhaes; F Ferriolli Filho; A O Luquetti
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Nov-Dec       Impact factor: 2.184

9.  Characterization of cytokine production in murine Trypanosoma cruzi infection by in situ immunocytochemistry: lack of association between susceptibility and type 2 cytokine production.

Authors:  L Zhang; R L Tarleton
Journal:  Eur J Immunol       Date:  1996-01       Impact factor: 5.532

10.  Studies of Trypanosoma cruzi clones in inbred mice. I. A comparison of the course of infection of C3H/HEN- mice with two clones isolated from a common source.

Authors:  M Postan; J A Dvorak; J P McDaniel
Journal:  Am J Trop Med Hyg       Date:  1983-05       Impact factor: 2.345

View more
  39 in total

1.  Dominant T- and B-cell epitopes in an autoantigen linked to Chagas' disease.

Authors:  N Gironès; C I Rodríguez; E Carrasco-Marín; R F Hernáez; J L de Rego; M Fresno
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

Review 2.  Chagas' disease and the autoimmunity hypothesis.

Authors:  F Kierszenbaum
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

3.  Oxidative stress and intracellular infections: more iron to the fire.

Authors:  Norma W Andrews
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

4.  Amiodarone inhibits Trypanosoma cruzi infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro.

Authors:  Daniel Adesse; Eduardo Meirelles Azzam; Maria de Nazareth L Meirelles; Julio A Urbina; Luciana R Garzoni
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

5.  Cell-specific activation of nuclear factor-kappaB by the parasite Trypanosoma cruzi promotes resistance to intracellular infection.

Authors:  B S Hall; W Tam; R Sen; M E Pereira
Journal:  Mol Biol Cell       Date:  2000-01       Impact factor: 4.138

6.  Soluble platelet selectin (sP-selectin) and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease during therapy with benznidazole in children with indeterminate form of Chagas' disease.

Authors:  S A Laucella; E L Segura; A Riarte; E S Sosa
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

7.  Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi.

Authors:  Silvia I Cazorla; Pablo D Becker; Fernanda M Frank; Thomas Ebensen; María J Sartori; Ricardo S Corral; Emilio L Malchiodi; Carlos A Guzmán
Journal:  Infect Immun       Date:  2007-10-29       Impact factor: 3.441

8.  Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection.

Authors:  B Wizel; N Garg; R L Tarleton
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

9.  Immunopathologic characterization of naturally acquired Trypanosoma cruzi infection and cardiac sequalae in cynomolgus macaques (Macaca fascicularis).

Authors:  Harshan Pisharath; Chih-Ling Zao; John Kreeger; Susan Portugal; Thomas Kawabe; Tarea Burton; Lisa Tomaeck; Ahmed Shoieb; Brandy Morenko Campbell; Judy Franco
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-09       Impact factor: 1.232

10.  Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses.

Authors:  B Wizel; M Palmieri; C Mendoza; B Arana; J Sidney; A Sette; R Tarleton
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.